🕒 Monday 13 July 2026 Mon, 13 July 2026

Babylon Pump & Power has secured $0.4 million in convertible loans from key shareholders and plans a $12.7 million rights issue at a 35% discount to address working capital shortfalls and reduce debt.

H2G Limited has received a $774,632.77 R&D tax incentive refund, reinforcing its cash reserves and supporting its renewable energy strategy through 2027. The company plans to update shareholders on progress in its upcoming quarterly report.

Resolution Minerals has completed 16 diamond core holes totalling 4,470 metres at its Golden Gate South prospect in Idaho, progressing one third of its 2026 drill program aimed at defining gold and tungsten mineralisation.

The Federal Court has approved Advanced Innergy Solutions’ takeover of Matrix Composites, triggering the final steps toward Matrix’s ASX delisting by late July 2026.

Mayfield Group Holdings is set to acquire Nilsen's Switchboards Division for $4 million, adding 66 skilled employees and the N-Series product platform to boost manufacturing capacity and revenue.

Paradigm Biopharmaceuticals has secured US$3 million in its latest tranche under a US$27 million convertible note facility, bolstering funding for its global Phase 3 trial of injectable pentosan polysulfate sodium in knee osteoarthritis.

G11 Resources has confirmed a significant 90m zone of hydrothermal alteration at its Zig Zag target in Tasmania, with further drilling and surveys underway to test the open-ended geophysical anomaly.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

McLaren Minerals has wrapped up its largest-ever drilling campaign at the McLaren Titanium Project on schedule and within budget, setting the stage for a Mineral Resource update and maiden Ore Reserve estimate.

Toubani Resources has secured a US$208 million funding package combining a US$160 million gold stream and a US$48 million equity raise, ensuring Kobada Gold Mine construction stays on track for first gold in Q3 2027.

Clara Resources’ maiden field program at Mareeba Gold Project confirms high-grade gold assays up to 27.3 g/t, validates LiDAR targets, and establishes a 3D vein model to guide upcoming drilling.

Arafura Rare Earths has secured $361.5 million before costs through a combined placement and share purchase plan, issuing approximately 44.4 million new shares under the SPP and leaving a notable shortfall.

Latrobe Magnesium has secured a binding $16 million funding deal with Long State Investment to complete commissioning and expand its Demonstration Plant, marking a crucial step towards commercial magnesium metal production.

BPH Global has kicked off direct seaweed exports to China, reporting AUD 535,895 in sales for the latest trading period and expanding its footprint beyond Indonesia.

ABx Group’s ALCORE subsidiary has begun civil construction at its Bell Bay pilot plant, advancing a novel process to produce hydrogen fluoride from aluminium smelter by-products, addressing Australia’s dependence on imports.

State Gas Limited clears a year-long ATO review to access $4.1 million in R&D tax concessions, enabling debt repayment and bolstering cash reserves. Meanwhile, independent certification of 30.2 petajoules of 2P gas reserves at Rolleston West strengthens its development prospects.

WAM Active has posted a staggering 75.5% investment portfolio gain for FY2026, far outpacing benchmarks, and announced increased fully franked dividends including a special payout.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Estrella Resources (ASX: ESR) has revealed striking high-grade copper and manganese assay results from its Timor-Leste concessions, spotlighting a vast geological dome that could underpin a new multi-commodity mineral province.

WCM Global Growth Limited delivered a stellar 19.28% return in the June quarter, outpacing its MSCI benchmark, while announcing a series of progressive fully franked dividends through FY2027.

Island Pharmaceuticals has secured a critical collaboration with Texas Biomedical Research Institute to advance dose optimisation for its antiviral Galidesivir, targeting Marburg Virus Disease under the FDA Animal Rule. This second phase complements ongoing USAMRIID efforts and aims to de-risk pivotal study design with data from 32 non-human primates.

Janus Electric has secured a A$10 million order from US fleet Ability Tri-Modal, lifting its North American diesel-to-electric truck conversions to 45 and advancing commercial rollouts in Canada and Australia.

Stelar Metals has revealed multiple rock chip assays exceeding 1% WO3 at its Hill of Leaders Project, marking a significant new tungsten discovery in the Northern Territory. The company is fast-tracking drilling to test the system's scale amid tightening global tungsten supply.

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.